Affordable Access

[Osteoprotegerin (OPG/OCIF) inhibits bone destruction in rheumatoid arthritis models].

Authors
Type
Published Article
Journal
Clinical calcium
Publication Date
Volume
11
Issue
5
Pages
602–607
Identifiers
PMID: 15775561
Source
Medline
License
Unknown

Abstract

Recent discovery of factors involved in bone destruction in Rheumatoid Arthritis (RA) identified its molecular mechanism. Osteoclast differentiation factor (ODF, also called receptor activator of NF-kappaB ligand (RANKL) ) that controls osteoclast differentiation and function has a major role in the bone destruction among them. Osteoclastogenesis inhibitory factor (OCIF, also called osteoprotegerin (OPG) ) that is a decoy receptor for ODF/RANKL is a specific inhibitor of bone destruction. OPG/OCIF may be useful for and applicable to the treatment of bone destruction in RA.

Statistics

Seen <100 times